jazz pharmaceuticals plc (nasdaq: jazz) is an international biopharmaceutical company focused on improving patients’ lives by identifying, developing and commercializing meaningful products that address unmet medical needs. we are a diverse company of over 875 employees focused on portfolio of products and/or product candidates in the areas of sleep, hematology/oncology and pain. founded in 2003 and headquartered in dublin, ireland, jazz pharmaceuticals has u.s. offices in palo alto, ca and philadelphia, pa, and has offices in various other locations in europe. the company’s maintains a highly collaborative and entrepreneurial culture where employees focus on how they accomplish success as well as what is done to accomplish results by operating in accordance with the company’s core values: integrity, collaboration, passion, innovation and the pursuit of excellence. we plan to build upon our portfolio of products through acquisition and/or in-licensing activities, and leveraging our uni

Company profile
Ticker
JAZZ
Exchange
Website
CEO
Bruce Cozadd
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
JAZZ PHARMACEUTICALS INC
SEC CIK
Corporate docs
Subsidiaries
Jazz Pharmaceuticals Ireland Limited • GW Pharma Limited • Jazz Pharmaceuticals, Inc. • Celator Pharmaceuticals Inc. • GW Research Limited • Gentium S.r.l. • Jazz Pharmaceuticals UK Holdings Limited • Jazz Financing Holdings Limited • Jazz Pharmaceuticals International Limited • Jazz Investments Europe Limited ...
IRS number
981032470
JAZZ stock data
Latest filings (excl ownership)
10-Q
2023 Q3
Quarterly report
8 Nov 23
8-K
Jazz Pharmaceuticals Announces Third Quarter 2023 Financial Results and Updates Financial Guidance
8 Nov 23
8-K
Departure of Directors or Certain Officers
12 Sep 23
10-Q
2023 Q2
Quarterly report
9 Aug 23
8-K
Jazz Pharmaceuticals Announces Second Quarter 2023 Financial Results and Raises 2023 Full Year Financial Guidance
9 Aug 23
DEFA14A
Additional proxy soliciting materials
26 Jul 23
CT ORDER
Confidential treatment order
11 Jul 23
8-K
Regulation FD Disclosure
22 Jun 23
ARS
2022 FY
Annual report to shareholders
16 Jun 23
DEFA14A
Additional proxy soliciting materials
16 Jun 23
Transcripts
JAZZ
Earnings call transcript
2023 Q3
8 Nov 23
JAZZ
Earnings call transcript
2023 Q2
9 Aug 23
JAZZ
Earnings call transcript
2023 Q1
10 May 23
JAZZ
Earnings call transcript
2022 Q4
1 Mar 23
JAZZ
Earnings call transcript
2022 Q3
10 Nov 22
JAZZ
Earnings call transcript
2022 Q2
3 Aug 22
JAZZ
Earnings call transcript
2022 Q1
5 May 22
JAZZ
Earnings call transcript
2021 Q4
2 Mar 22
JAZZ
Earnings call transcript
2021 Q3
10 Nov 21
JAZZ
Earnings call transcript
2021 Q2
4 Aug 21
Latest ownership filings
4
Mark Douglas Smith
6 Dec 23
4
Jennifer E. Cook
6 Dec 23
4
RENEE D GALA
14 Nov 23
SC 13G/A
VANGUARD GROUP INC
11 Sep 23
4
Neena M Patil
6 Sep 23
144
Notice of proposed sale of securities
1 Sep 23
4
Patricia Carr
31 Aug 23
144
Notice of proposed sale of securities
29 Aug 23
4
Neena M Patil
17 Aug 23
4
Anne ORiordan
15 Aug 23
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Institutional ownership, Q3 2023
87.4% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 468 |
Opened positions | 62 |
Closed positions | 51 |
Increased positions | 154 |
Reduced positions | 176 |
13F shares | Current |
---|---|
Total value | 7.11 tn |
Total shares | 55.04 mm |
Total puts | 94.80 k |
Total calls | 134.42 k |
Total put/call ratio | 0.7 |
Largest owners | Shares | Value |
---|---|---|
BLK Blackrock | 7.19 mm | $930.27 bn |
Vanguard | 6.38 mm | $825.70 bn |
LSV Asset Management | 2.37 mm | $306.58 bn |
STT State Street | 2.33 mm | $300.95 bn |
Wellington Management | 1.67 mm | $215.97 bn |
JPM JPMorgan Chase & Co. | 1.43 mm | $184.59 bn |
Samlyn Capital | 1.36 mm | $175.89 bn |
FMR | 1.33 mm | $172.56 bn |
Renaissance Technologies | 1.31 mm | $169.00 bn |
AMP Ameriprise Financial | 1.30 mm | $168.22 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
4 Dec 23 | Cook Jennifer E. | Ordinary Shares | Sell | Dispose S | No | No | 119.27 | 417 | 49.74 k | 6,888 |
4 Dec 23 | Smith Mark Douglas | Ordinary Shares | Sell | Dispose S | No | No | 119.27 | 417 | 49.74 k | 6,888 |
10 Nov 23 | Gala Renee D | Ordinary Shares | Grant | Acquire A | No | No | 0 | 772 | 0.00 | 36,887 |
1 Sep 23 | Neena M Patil | Ordinary Shares | Sell | Dispose S | No | Yes | 144.25 | 1,500 | 216.38 k | 29,186 |
29 Aug 23 | Patricia Carr | Ordinary Shares | Sell | Dispose S | No | No | 143.4686 | 142 | 20.37 k | 5,986 |
News
Japan Approves Marijuana-Derived Medicines, Adopt 7-Year Prison Sentences For Recreational Use
6 Dec 23
Truist Securities Reiterates Buy on Jazz Pharmaceuticals, Maintains $200 Price Target
4 Dec 23
Jazz Pharmaceuticals To Present Long-Term And Real-World Data Emphasizing Commitment To Treatment-Resistant Epilepsy At The 2023 American Epilepsy Society Annual Meeting
1 Dec 23
Australian MPs Admit They Tried Cannabis, Signaling Policy Reform & Epidiolex For Seizures Approved In Canada
30 Nov 23
Needham Reiterates Buy on Jazz Pharmaceuticals, Maintains $225 Price Target
29 Nov 23
Press releases
Jazz Pharmaceuticals to Present Long-Term and Real-World Data Emphasizing Commitment to Treatment-Resistant Epilepsy at the 2023 American Epilepsy Society Annual Meeting
1 Dec 23
Jazz Pharmaceuticals to Present New Data Highlighting Advancements in Solid Tumors and Rare Blood Cancers at Upcoming Oncology Meetings
30 Nov 23
Autifony Announces Exclusive Global License and Collaboration Agreement with Jazz Pharmaceuticals on Two Ion Channel Targets for Neurological Disorders
14 Nov 23
Ligand Reports Third Quarter 2023 Financial Results
8 Nov 23
Global Cancer Vaccines Market Share Is Expected To Reach $19.27 Billion By 2030
25 Oct 23